AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 207 filers reported holding AMICUS THERAPEUTICS INC in Q1 2018. The put-call ratio across all filers is 0.53 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $492,480 | -93.5% | 40,500 | -94.1% | 0.02% | -94.5% |
| Q1 2023 | $7,585,050 | +57.5% | 683,954 | +73.4% | 0.31% | +29.5% |
| Q4 2022 | $4,815,758 | +1154.1% | 394,411 | +873.9% | 0.24% | +1216.7% |
| Q1 2022 | $384,000 | -81.2% | 40,500 | -77.2% | 0.02% | -84.1% |
| Q4 2021 | $2,048,000 | +2.2% | 177,346 | -15.5% | 0.11% | +11.9% |
| Q3 2021 | $2,004,000 | +413.8% | 209,835 | +424.6% | 0.10% | +260.7% |
| Q4 2019 | $390,000 | -80.3% | 40,000 | -83.8% | 0.03% | -81.1% |
| Q3 2019 | $1,982,000 | -37.7% | 247,046 | +16.7% | 0.15% | +9.6% |
| Q1 2018 | $3,183,000 | -19.3% | 211,618 | -22.8% | 0.14% | -34.8% |
| Q4 2017 | $3,945,000 | -35.2% | 274,122 | -32.1% | 0.21% | -32.6% |
| Q3 2017 | $6,085,000 | +826.2% | 403,500 | +354.4% | 0.31% | +729.7% |
| Q3 2016 | $657,000 | -66.8% | 88,800 | -51.2% | 0.04% | -69.7% |
| Q1 2015 | $1,976,000 | -40.6% | 182,000 | -54.5% | 0.12% | -69.0% |
| Q4 2014 | $3,328,000 | – | 400,000 | – | 0.39% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |